FindCure Biosciences Completes Tens of Millions Series A Financing to Accelerate Clinical Development of Axl Inhibitor FC084

VCBeat News learned that Vanencell Biotech (Zhongshan) Co., Ltd. (FindCure Biosciences) recently announced the completion ofTens of millions of yuan in Series A financing.This round of financing was jointly participated in by Hecheng Capital, Huaying Health, Renxi Fund, Yishang Huicheng, and Dilianxing. The funds raised will be used forAccelerate the clinical research of the Axl inhibitor FC084,as well as the development of other clinical and preclinical investigational projects, striving to provide better therapeutic solutions for cancer patients.

FindCure, established in December 2019, is a high-tech innovative biopharmaceutical enterprise driven by exceptional independent R&D capabilities. Co-founded by Dr. Xi Ning, a renowned industry expert, and Professor Yuan Xueli, a clinical oncology specialist, the company’s management team boasts an average of over 20 years of domestic and international R&D and management experience. Focusing on areas with significant unmet medical needs, such as lung cancer and gastric cancer, FindCure specializes in the development of drugs targeting signaling pathways and immunotherapy, committed to bringing “First-in-class” and “Best-in-class” therapies with breakthrough potential to the global market.

▲ FindCure’s R&D Laboratory in Zhongshan, Guangdong

The company has currently established operations in Zhongshan, GuangdongOver 1,000 square metersR&D laboratory, equipped with comprehensive capabilities in preclinical R&D, translational medicine, and clinical research, to fully meet the needs of the preclinical stage of innovative drug development.

Dr. Xi Ning, Founder and CEO, stated:“We extend our gratitude to the investors participating in this funding round for their support of FindCure. Successfully securing this new round of financing amid a challenging market environment further demonstrates our shareholders’ trust in our team and recognition of the company’s innovative capabilities. We will remain true to our original mission, pursue continuous innovation, vigorously advance clinical trials of our pipeline candidates, and proactively plan for subsequent product development. We are confident that, with the support of our shareholders, we will accelerate the commercialization of our products and provide patients with better therapeutic options.”

Professor Yuan Xueli, Co-founder and CSO, stated:“FindCure remains committed to addressing the clinical needs of cancer patients through innovative technologies and has built a robust product pipeline. Among these, the selective Axl inhibitor FC084 and the Type II MET inhibitor FC413 have both entered Phase I clinical trials, while the PI3Kγ inhibitor FC919 is currently undergoing preparations for Investigational New Drug (IND) application. Looking ahead, we will continue to accelerate the development of our products in China and globally through independent R&D, collaborative development, and out-licensing. We anticipate obtaining clinical data for our core product, FC084, in the near term to facilitate its early commercialization.”

Zhuhai Hecheng Zhiyi Capital Management Co., Ltd. was established in Hengqin in 2015. As a venture capital firm, it is dedicated to professionalism and leveraging financial resources with collective intelligence, focusing on investing in and incubating innovative enterprises with “hardcore technologies”; strengthening platform enterprises driven by digital technologies and data; and cultivating and empowering “chain leader” enterprises with industry-leading capabilities.

Zhongshan Huaying Health Investment Fund Partnership (Limited Partnership) is a local state-owned industrial investment fund established in the Torch Development Zone of Zhongshan City, in accordance with relevant policies such as the Outline Development Plan for the Guangdong-Hong Kong-Macao Greater Bay Area and the Action Plan for the Development of the Health and Pharmaceutical Industry in Zhongshan City. The fund primarily invests in the healthcare and wellness sector, including innovative pharmaceuticals, medical devices, medical artificial intelligence technologies, in vitro diagnostics, and medical big data. Leveraging government resources in the Zhongshan Torch Development Zone, such as the National Health Technology Industrial Base and the Guangdong Provincial Strategic Emerging Industry Base for Health and Pharmaceuticals, Huaying Health Fund will provide comprehensive corporate services to health and pharmaceutical enterprises settling in Zhongshan City.

Hubei Renxi Technology Innovation Industrial Investment Private Equity Fund Management Co., Ltd. was established in Jianghan District, Wuhan City, Hubei Province. The firm specializes in primary equity investments in the healthcare and wellness sector. Its team is committed to pursuing an active yet prudent investment strategy in leading domestic biopharmaceutical enterprises, including those focused on innovative biopharmaceuticals, innovative medical devices, and R&D and manufacturing of core medical materials that address critical technological bottlenecks. The company’s founder and core team members possess extensive experience in investment and mergers and acquisitions within the healthcare and wellness industry. They are proficient in corporate due diligence and analysis, financial modeling, risk control, strategic planning, and valuation negotiations, and have successfully executed multiple projects.

Beijing Yishang Huicheng Venture Capital Center (Limited Partnership) is a venture capital fund that makes equity investments in technologically innovative companies within China’s biomedical sector. Jointly established by well-known listed pharmaceutical companies, government industrial guidance funds, and other partners, the fund focuses on new drug development, novel biotechnological therapies, and new drug R&D service organizations. Yishang Huicheng is committed to seizing industry opportunities and pooling professional expertise, facilitating corporate collaboration through resource integration and fostering mutual growth with portfolio companies through investment empowerment.